"I mean BT was supposed to be given for Phase 2 drugs, not completed Phase 3...although I suppose the FDA can decide whatever they want."

Prior to Phase 3 BETonMACE, there have not been any apabetalone trials with pre-specified kidney function endpoints or pre-specified CKD population. So your point about apabetalone Phase 2 trials being justification for renal BTD is somewhat irrelevant. All apabetalone renal data to data has been post-hoc. Only exception was the extremely small (16 patients) and short (one week) New Zealand Phase 1 trial in end stage renal disease patients. Pre-specified and not post-hoc is important distinction.

BDAZ